Your browser doesn't support javascript.
Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak.
de la Cruz-Benito, Beatriz; Lázaro-Del Campo, Paula; Ramírez-López, Andrés; de Soto-Álvarez, Teresa; Sánchez-Vadillo, Irene; García-Pérez, Eduardo; Dos Santos-Ortas, Abel; Humala-Barbier, Karem; López-de la Guía, Ana; Casado-Abad, Gema; Jiménez-Yuste, Victor; Canales-Albendea, Miguel.
  • de la Cruz-Benito B; Haematology Department, La Paz University Hospital, Madrid, Spain.
  • Lázaro-Del Campo P; Haematology Department, La Paz University Hospital, Madrid, Spain.
  • Ramírez-López A; Haematology Department, La Paz University Hospital, Madrid, Spain.
  • de Soto-Álvarez T; Haematology Department, La Paz University Hospital, Madrid, Spain.
  • Sánchez-Vadillo I; Haematology Department, La Paz University Hospital, Madrid, Spain.
  • García-Pérez E; Haematology Department, La Paz University Hospital, Madrid, Spain.
  • Dos Santos-Ortas A; Haematology Department, La Paz University Hospital, Madrid, Spain.
  • Humala-Barbier K; Haematology Department, La Paz University Hospital, Madrid, Spain.
  • López-de la Guía A; Haematology Department, La Paz University Hospital, Madrid, Spain.
  • Casado-Abad G; Pharmacy Department, La Paz University Hospital, Madrid, Spain.
  • Jiménez-Yuste V; Haematology Department, La Paz University Hospital, Madrid, Spain.
  • Canales-Albendea M; Haematology Department, La Paz University Hospital, Madrid, Spain.
Br J Haematol ; 191(3): 386-389, 2020 11.
Article in English | MEDLINE | ID: covidwho-697165
ABSTRACT
The COVID-19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment who represent a vulnerable population for SARS-CoV-2 infection. Aggressive lymphoid neoplasms, such as diffuse large B cell lymphoma and high-grade B cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed to minimise the risk of SARS-CoV-2 infection while continuing haematological treatment. In this report, we analyse the management of front-line therapy in 18 patients during the COVID-19 outbreak, as well as the results of the implemented measures in their outcome.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Lymphoma, Large B-Cell, Diffuse / Pandemics / Plasmablastic Lymphoma / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study Topics: Long Covid Country/Region as subject: Europa Language: English Journal: Br J Haematol Year: 2020 Document Type: Article Affiliation country: Bjh.17066

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Lymphoma, Large B-Cell, Diffuse / Pandemics / Plasmablastic Lymphoma / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study Topics: Long Covid Country/Region as subject: Europa Language: English Journal: Br J Haematol Year: 2020 Document Type: Article Affiliation country: Bjh.17066